Therapy Name | LY2880070 + Gemcitabine |
Therapy Description |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Gemcitabine | Gemzar | Difluorodeoxycytidine Hydrochlorothiazide | Chemotherapy - Antimetabolite 10 | Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary). |
LY2880070 | ESP-01 | CHK1 Inhibitor 14 | LY2880070 selectively inhibits CHK1, which potentially results in increased response to chemotherapeutic agents (PMID: 28331049). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|---|---|---|---|
NCT02632448 | Phase Ib/II | LY2880070 + Gemcitabine LY2880070 | A Study of LY2880070 in Patients With Advanced or Metastatic Cancer | Recruiting |